Quarterly Result: Marksans Pharma Ltd

Technical View: 

Marksans Pharma Ltd., ended at Rs. 47.55, down by 1.5 points or 3.06% from its earlier closing of Rs. 49.05 on the BSE.
The scrip touched a high and low of Rs. 49.1 and Rs. 45.2 respectively, after opening at 49.1. In totality 861325(NSE+BSE) shares have been traded on the counter; and the stock is trading above its 50 DMA.

Consolidated Results Q2FY17:

Bloomberg estimates were higher than Marksans Pharma Ltd’s actual Q2FY17 consolidated numbers. Revenue for the period has come in 10.9% lesser than the estimate of Rs 210 cr. Net profit for the period has come in 95.8% lesser than the estimate of Rs 11 cr.

The quarter's revenue has dipped 26.8% yoy to Rs 187.13 cr. This can be attributed to 43.6% drop to Rs 137.25 cr in revenues from Europe, UK business as compared to H1FY16.

Madison's EBITDA has dropped by 87.4% yoy to Rs 6.47 cr while EBITDA margins have shrunken 1,665 bps yoy to 3.5%. This is mainly driven by operating expenses remaining stable yoy even though there is drop in revenues of 26.8% yoy.

The company's net profit has depleted by 98.7% yoy to Rs 0.48 cr. Finance cost has dropped 63% yoy.